MCUR—The clinical-trial change for the VLU phase-3 trial in the previous post is that there will no longer be an interim analysis for efficacy, but rather a futility analysis that will consume no alpha.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.